Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Merck & Co. focuses on farnesyltransferase inhibitors

Oct. 7, 1997

Kyowa Hakko's cytostatic agents progress in U.S. clinical trials

Oct. 6, 1997

Clinical pharmacokinetic study of panomifene described

Oct. 6, 1997

Gd-Tex in phase Ib: safety profile and maximum tolerated dose

Oct. 6, 1997

Femara launched in U.S.

Oct. 3, 1997

Sugen's angiogenesis inhibitor SU-5416 enters phase I

Oct. 3, 1997

Favorable phase II/III data for Targretin in CTCL reported at dermatology congress

Oct. 2, 1997

Safety profile of VRCTC-310 established in rabbits

Oct. 2, 1997

Camptosar available in Canada

Oct. 1, 1997

Matrix announces restructuring to focus on oncology products

Oct. 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.